These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16253926)

  • 21. Understanding drug-induced torsades de pointes: a genetic stance.
    Kannankeril PJ
    Expert Opin Drug Saf; 2008 May; 7(3):231-9. PubMed ID: 18462182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
    Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
    Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined pharmacological block of I(Kr) and I(Ks) increases short-term QT interval variability and provokes torsades de pointes.
    Lengyel C; Varró A; Tábori K; Papp JG; Baczkó I
    Br J Pharmacol; 2007 Aug; 151(7):941-51. PubMed ID: 17533421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequency of high-risk use of QT-prolonging medications.
    Allen LaPointe NM; Curtis LH; Chan KA; Kramer JM; Lafata JE; Gurwitz JH; Raebel MA; Platt R
    Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):361-8. PubMed ID: 16178046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Terfenadine should be withdrawn from clinical use.
    Khilnani G
    J Assoc Physicians India; 1999 Sep; 47(9):943. PubMed ID: 10778682
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug-induced QTC prolongation dangerously underestimates proarrhythmic potential: lessons from terfenadine.
    Hondeghem LM; Dujardin K; Hoffmann P; Dumotier B; De Clerck F
    J Cardiovasc Pharmacol; 2011 May; 57(5):589-97. PubMed ID: 21346598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes.
    Lehtonen A; Fodstad H; Laitinen-Forsblom P; Toivonen L; Kontula K; Swan H
    Heart Rhythm; 2007 May; 4(5):603-7. PubMed ID: 17467628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes.
    Lin YL; Kung MF
    Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):235-9. PubMed ID: 19145580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-induced torsades de pointes: the evolving role of pharmacogenetics.
    Fitzgerald PT; Ackerman MJ
    Heart Rhythm; 2005 Nov; 2(2 Suppl):S30-7. PubMed ID: 16253929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
    Ahmad K; Dorian P
    Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long QT syndrome: reduced repolarization reserve and the genetic link.
    Roden DM
    J Intern Med; 2006 Jan; 259(1):59-69. PubMed ID: 16336514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs.
    Hondeghem LM
    J Cardiovasc Electrophysiol; 2006 Mar; 17(3):337-40. PubMed ID: 16643415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacologic agents associated with QT interval prolongation.
    Olsen KM
    J Fam Pract; 2005 Jun; Suppl():S8-S14. PubMed ID: 15938993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Torsades de pointes occurring in association with terfenadine use.
    Monahan BP; Ferguson CL; Killeavy ES; Lloyd BK; Troy J; Cantilena LR
    JAMA; 1990 Dec; 264(21):2788-90. PubMed ID: 1977935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Extension of QT interval as a consequence of risk factor accumulation--case study].
    Sisáková M; Toman O; Floriánová A; Kadlecová J; Chroust K; Papousek I; Spinar J
    Vnitr Lek; 2006 Mar; 52(3):271-3. PubMed ID: 16722159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Torsade de Pointes tachycardia during sotalol treatment of a patient with normal potassium levels].
    Appel JM; Sigurd B
    Ugeskr Laeger; 1996 Jul; 158(28):4093-4. PubMed ID: 8701528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early clinical development: evaluation of drug-induced torsades de pointes risk.
    Vik T; Pollard C; Sager P
    Pharmacol Ther; 2008 Aug; 119(2):210-4. PubMed ID: 18601950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ciprofloxacin-induced acquired long QT syndrome.
    Prabhakar M; Krahn AD
    Heart Rhythm; 2004 Nov; 1(5):624-6. PubMed ID: 15851230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Negative electro-mechanical windows are required for drug-induced Torsades de Pointes in the anesthetized guinea pig.
    Guns PJ; Johnson DM; Weltens E; Lissens J
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):125-34. PubMed ID: 22516473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measuring the risk of torsades de pointes: electrocardiographic evaluation of PNU-142093 in conscious cynomolgus non-human primates using restraint and non-restraint procedures.
    Bass AS; Hanson LA; Jackson TA
    J Pharmacol Toxicol Methods; 2009; 60(1):51-7. PubMed ID: 19447184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.